comparemela.com

Latest Breaking News On - Pauline funchain - Page 2 : comparemela.com

New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access

New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access

Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

 E-Mail IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more  Credit: Huntsman Cancer Institute PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.